A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues

Author(s): Rithika Mary Koshy, Cornelius James Fernandez*, Koshy Jacob

Journal Name: Current Drug Safety

Volume 16 , Issue 2 , 2021

Become EABM
Become Reviewer
Call for Editor


A large proportion of persons with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) do not reach the glycosylated haemoglobin (HbA1c) target of < 7% (53 mmol/- mol), with an increasing proportion of them being overweight or obese. In both T1DM and T2DM, there is accelerated gastric emptying and postprandial hyperglucagonemia. Furthermore, insulin therapy itself is associated with risk of hypoglycemia and weight-gain both of which are barriers to achieving good control. Medications which can achieve significant HbA1c and weight reduction associated with an ability to delay gastric emptying and suppress the glucagon secretion with minimal/ no hypoglycemia are of particular interest as an adjuvant to insulin. A synthetic amylin analogue, pramlintide is a drug with above mentioned properties. Other medications with similar properties are glucagon-like peptide-1 receptor agonists (GLP-1 RAs). In this article, we will review the efficacy of pramlintide when given with insulin in improving HbA1c, weight, and cognition with- /without GLP-1 RAs as well as its cardiovascular (CV) safety.

Keywords: Amylin analogues, pramlintide, diabetes mellitus, cardiovascular safety, postprandial hyperglucagonemia, glycosylated haemoglobin, pramlintide.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Page: [129 - 141]
Pages: 13
DOI: 10.2174/1574886315999201105153852
Price: $95

Article Metrics

PDF: 26